Large two-biobank association resource
The study meta-analyses 11 prescription-derived phenotypes across UK Biobank and FinnGen, with overall sample sizes reaching 692,039 participants.
↳ Results, Discovery of 140 Genetic Associations; Table 1
Abstract
Pain-related conditions are the leading cause of disability worldwide. Existing GWAS for chronic pain have mainly focused on individual pain-related disorders, which may not optimally capture the phenotype. Here, we define chronic pain based on prescription analgesic use ( ≥ 90 days) in two large biobanks (UK Biobank and FinnGen). GWAS meta-analyses of 11 prescription-based pain phenotypes identify 140 associations with chronic pain, including 78 novel (e.g. ARPP21, CNTNAP2) and 62 previously reported (e.g. SLC39A8, DCC, TRPM8) associations. Integrating these genetic associations with functional data including transcriptome-wide association studies, cell-type and pathway enrichment, and gene enrichment in mouse phenotypes identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling. Our study showcases how the use of prescription data to identify and characterize pain can provide insights into pain genetics and its underlying biology.
Key Claims
Primary findingTentative
Integrating these genetic associations with functional data identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling.
functional enrichments are indirect and inherit uncertainty from the prescription-based phenotype
Abstract
SecondaryTentative
We detected many associations at loci previously reported in the literature, demonstrating that our prescription-based definitions of chronic pain are capturing relevant disease information.
known-locus overlap cannot separate pain signal from medication-use and opioid-related determinants
Results, Discovery of 140 Genetic Associations
SecondarySupported
The strongest genetic correlations were found between pain duration phenotypes and depression or post-traumatic stress disorder.
reported LDSC estimates pass the stated multiple-testing threshold, subject to proxy-phenotype interpretation
Results, Shared Genetic Architecture of Pain with Neuropsychiatric and Immunological Traits
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Broad complementary analytical programme
Common-variant GWAS is supplemented by rare-variant burden tests, colocalisation, TWAS, cell-type analysis, mouse-phenotype enrichment, and genetic-correlation analyses.
↳ Methods, Overview of Analyses; Figure 6
Substantive discussion of study boundaries
The Discussion identifies restrictions arising from European ancestry, UK and Finnish healthcare systems, prescription ascertainment, and use of a UK Biobank LD reference for Finnish data.
↳ Discussion, limitations paragraphs
Limitations
Prescription proxy lacks direct validation
The phenotype assumes 30-day prescriptions and combines diverse analgesics, while prolonged prescribing can reflect factors other than chronic pain. No direct comparison with diagnosis-based or patient-reported pain in the same cohorts is presented.
↳ Methods, Phenotype Definitions; Discussion, limitations paragraph
Headline counts are inconsistently presented
The Abstract reports 78 novel and 62 previously reported associations, but Table 1 sums to approximately 85 novel and 55 previously reported signals. The total of 140 also aggregates results across 11 overlapping phenotypes rather than representing 140 unique loci.
↳ Abstract; Table 1; Discussion, paragraph 1
Biological interpretations exceed tested contrasts
Sex specificity is inferred from significant-versus-nonsignificant findings without a reported heterogeneity test, and functional enrichments remain hypothesis-generating rather than validated mechanisms.
↳ Results, Sex-Stratified Analysis and Functional Analysis; Discussion, paragraph 3
Nabu Commentary
The study’s scale, two-biobank design, and extensive downstream analyses support a meaningful contribution to association mapping for analgesic-use phenotypes. Methodological Rigour is limited by the assumption that extended prescriptions directly identify chronic pain and by the absence of sensitivity analyses separating pain from prescribing behaviour, opioid response, or dependence. The Abstract’s novel/known split is not reproduced by Table 1, and the 140-signal total is not equivalent to a count of unique loci. The Discussion addresses several population and ascertainment limitations, but mechanistic and sex-specific interpretations remain stronger than the reported analyses warrant.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.4
Confidence mediumContribution
3.6
The study meaningfully extends prescription-derived pain genetics through a large two-biobank meta-analysis and several downstream analyses. Its contribution is moderated by overlapping phenotype counts, an inconsistent novel/known split, and limited functional validation.
Abstract; Results, Discovery of 140 Genetic Associations; Table 1
These combined meta-analyses identified 140 genome-wide associations
Methodological Rigour
3.1
The GWAS, meta-analysis, rare-variant, colocalisation, TWAS, and enrichment procedures are extensively described using established tools. The central phenotype remains an unvalidated treatment-use proxy, and the headline signal count aggregates overlapping phenotypes without conditional analysis.
Methods, Phenotype Definitions and Association Analyses; Table 1
We assumed that each analgesic prescription is for 30 days duration.
Reporting
3.5
The article follows a coherent sequence from phenotype construction through association discovery and functional interpretation. Precision is reduced by numerical discrepancies and by sex-specific and mechanistic interpretations that exceed the reported tests.
Results, Sex-Stratified Analysis; Figure 5 legend; Methods, SNP-Based Heritability and Genetic Correlations
male pain perception may be more genetically driven than female pain perception
Positioning
3.5
The paper engages prior pain GWAS and discusses ancestry, healthcare-system, LDSC, and ascertainment limitations. It does not fully propagate the multifactorial nature of analgesic prescribing into every claim about chronic-pain genes and mechanisms.
Introduction; Discussion, final three paragraphs
prescription drug use can be influenced by many factors
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
Several numerical and interpretive inconsistencies warrant caution, although they do not invalidate the underlying association analyses. The most consequential concern is that the reported novel/known split is not reproduced by Table 1.
Research ConductNoted
Ethics approval and consent are declared for both cohorts, and summary-statistic and code availability are stated. No competing-interest disclosure appears in the supplied text.
Flags: 3 declared / 5 total
Reference IntegrityClean
93 of 93 checkable references verified
97 references in manuscript 4 have no canonical index record — counted, but not index-checkable 5 references confirmed by manual review
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 08 Oct 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Mechanistic
The work identifies associations, prioritised genes, and enriched pathways but provides no experimental or clinical validation. Its immediate role is to direct future cellular and in vivo studies.
Discussion, concluding paragraph
This should help direct future cellular and in vivo studies to elucidate pain mechanisms.
AI-generated, human-governed. Something look off? Contact us to request a review.